Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac hypertrophy
β-adrenergic signaling is involved in the development of cardiac hypertrophy (CH), justifying the use of β-blockers as a therapy to minimize and postpone the consequences of this disease. Evidence suggests that adenylate cyclase, a downstream effector of the β-adrenergic pathway, might be a therapeutic target. We examined the effects of the anti-epileptic drug carbamazepine (CBZ), an inhibitor of adenylate cyclase. In a murine cardiac hypertrophy model, carbamazepine significantly attenuates isoproteronol (ISO)-induced cardiac hypertrophy. Carbamazepine also has an effect in transverse aortic banding induced cardiac hypertrophy (TAB) (P=0.07). When carbamazepine was given in combination with the antibiotic doxycycline (DOX), which inhibits matrix metalloproteinases (MMPs), therapeutic outcome measured by heart weight-to-body weight and heart weight-to-tibia length ratios was improved compared to either drug alone. Additionally, the combination therapy resulted in an increase in the survival rate over a 56-day period compared to that of untreated mice with cardiac hypertrophy or either drug used alone. Moreover, in support of a role for carbamaze - pine as a β-adrenergic antagonist via cAMP inhibition, a lower heart rate and a lower level of the activated phosphorylated form of the cAMP Response Element-Binding (CREB) were observed in heart extracts from mice treated with carbamazepine. Gene expression analysis identified 19 genes whose expression is significantly altered in treated animals and might be responsible for the added benefit provided by the combination therapy. These results suggest that carbamazepine acts as a β-adrenergic antagonist. Carbamazepine and doxycycline are approved by the US Food and Drug Administration (FDA) as drugs that might complement medications for cardiac hypertrophy or serve as an alternative therapy to traditional β- blockers. Furthermore, these agents reproducibly impact the expression of genes that may serve as additional therapeutic targets in the management of cardiac hypertrophy.
Cardiac hypertrophy, gene expression, drug repurposing, FDA approved.
Mounir Errami, Division of Translational Research, University of Texas Southwestern Medical Center, 2201 Inwood Road, Dallas, Texas 75390-9185, USA. E-mail: email@example.com
The authors wish to thank
Angela George, Robin Frink, Charles German and
Joe Steninger for excellent technical help, Dr
Wayne Fisher for discussions and comments and
Linda Gunn for administrative assistance. This
work was supported by the P.O’B. Montgomery
Distinguished Chair (HG), the Hudson
Foundation (HG) and National Institute of Health
cardiology fellowship (CLG).
Share this Article
Related Content In Heart Failure
Measurement of Blood Volume in Patients with Heart Failure: Clinical Relevance, Surrogates, Historical Background and Contemporary Methodology
Heart International. 2023;17(1):Online ahead of journal publication
Heart failure (HF) is a common clinical diagnosis often requiring hospitalization secondary to patient decompensation associated with clinically determined ‘dry’ or ‘wet’ volume states. However, fluid overload is the more common basis for clinical deterioration accounting for the majority of hospitalizations.1–4 There is often a cycle of decompensation, compensation following intervention and then a recurrence of volume overload […]
Natriuretic Peptide-guided Therapy for Heart Failure
Heart International. 2022;16(2):112–6 DOI: https://doi.org/10.17925/HI.2022.16.2.112
Heart failure (HF) is a complex syndrome caused by a variety of cardiac and non-cardiac diseases, and is associated with high mortality and hospitalization rates.1 Treatment has been traditionally based on a detailed history and physical examination. However, since cardiac biomarkers reflect the pathophysiology of HF, they add information to the clinical findings.1 The most widely used […]
Comparison of Speckle Tracking Echocardiography During Different Pacing Modalities for Cardiac Resynchronization Therapy Response Prediction
Heart International. 2022;16(1):64–70 DOI: https://doi.org/10.17925/HI.2022.16.1.64
Conventionally, according to the European Society of Cardiology pacing and cardiac resynchronization therapy (CRT) guidelines, patients with clinical heart failure and an echocardiographically measured left ventricular (LV) ejection fraction of <35% are considered for CRT implantation or standard right ventricular (RV) pacing (RVP) system upgrade.1 The recommendations for CRT typically follow failure to improve after 3 […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!